Class of antifungal agents including caspofungin, micafungin, and anidulafungin.
These agents are therapeutically equivalent.
Caspofungin found to be noninferior to amphotericin B in a candidemia study, although bordered on superiority secondary to the fact that amphotericin B had increased toxicity with increased withdrawal of patients from the study.
Studies have shown such agents to be noninferior to amphotericin B in efficacy, but not in terms of toxicity.
Anidulafungin noninferior to fluconazole for the treatment of candidiasis in a controlled study.
Equivalent to the two other classes of antifungal agents for anti candidal activity and should be considered as first line therapy on the basis of safety, toxicity and cost.